Top
Topic: Resistance to Cancer Immunotherapy

A special issue of Cancer Drug Resistance.

ISSN 2578-532X (Online)

Submission deadline: 31 Jan 2020

Guest Editor(s)

  • Prof. Gerhard Hamilton
    Department of Surgery, Medical University of Vienna, Vienna, Austria

    Website | E-mail

Special Issue Introduction

Cancer immunotherapy, especially in form of the inhibition of checkpoint molecules, has significantly improved the outlook of melanoma, lung cancer and other patients. However, of the approximately 45% of cancer patients eligible for immunotherapy only about 13% of cases are responders leaving the remaining population exposed to a therapy which has less side effects than chemotherapy but is not free of a range of adverse events. Assessment of PD-L1 expression and tumor mutational burden (TMB) enrich suitable patients but cannot actually predict responses. Furthermore, tumors may become resistant to immunotherapy either by changing their own characteristics or by generating an immunosuppressive microenvironment. For this issue, work on all aspects of mechanisms that renders immunotherapy ineffective is invited. This comprises the range of different immune checkpoint molecules and the modulation of their expression, tumor infiltration, immunosuppressive leukocyte populations as well as the effects of chemotherapy in combination trials and more. In particular, the ongoing study of drugs that can convert a cold tumor to a hot one or provide accessory stimulation of the immune system is of special interest to overcome resistance. Another current focus is the selection of markers to rapidly evaluate the success of an ongoing immunotherapy, including the detection of resistance. Future directions for the improvement of immunotherapy may involve combination therapy with other immune modulators, oncolytic viruses, vaccines, radiation treatment, chemotherapy, targeted therapy, or antiangiogenic therapy to achieve its full potential and to overcome resistance. In summary, the objective of this series is to explore the current successes and failures, and discuss the future directions of immunotherapy as a means of treating cancer.

Keywords

Cancer immunotherapy, checkpoint inhibition, resistance, CTLA-4, PD-L1, tumor mutational burden

Submission Deadline

31 Jan 2020

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://cdrjournal.com/pages/view/author_instructions
For Online Submission, please login at https://www.oaemesas.com/cdr
Submission Deadline: 31 Jan 2020
Contacts: Susan Song, Assistant Editor, editor_4@oaepublish.com
Bill Li, Managing Editor, bill.li@oaepublish.com or editorial@cdrjournal.com

Published Articles

This special issue is now open for submission.